Results 141 to 150 of about 72,840 (299)
No New Relevant Treatment Options for L-DOPA-Induced Dyskinesia from a Clinician's Point of View. [PDF]
Müller T.
europepmc +1 more source
Psychiatric Disorders and Apathy in Mixed Movement Disorders Linked to ADCY5 (MxMD‐ADCY5)
Abstract Background Mixed movement disorders linked to ADCY5 (MxMD‐ADCY5) represent a rare hyperkinetic movement disorder resulting from pathogenic variants in ADCY5. Psychiatric symptoms are suspected to be part of the phenotype. Objective The study aim was to assess psychiatric comorbidities in patients with MxMD‐ADCY5.
Aurélie Méneret +23 more
wiley +1 more source
Amantadine-induced livedo reticularis. [PDF]
Shima A, Yoshikawa S, Ueda T.
europepmc +1 more source
Asymmetric Upper Limb Dysfunction Demonstrated at the Bedside: A Phenomenology Video
Movement Disorders Clinical Practice, EarlyView.
Gero Lueg +4 more
wiley +1 more source
Abstract Objective Published reports on directional deep brain stimulation (DBS) have been limited to small, single‐center investigations. Therapeutic window (TW) is used to describe the range of stimulation amplitudes achieving symptom relief without side effects.
Alfons Schnitzler +24 more
wiley +1 more source
Shoulder Instability from Scapular Dyskinesia: How Rebalancing the Scapula Stabilizes the Shoulder. [PDF]
Wagner ER.
europepmc +1 more source
Early Cervical and Orofacial Variable Dystonia in Levodopa‐Naïve PRKN Parkinson's Disease
Movement Disorders Clinical Practice, EarlyView.
Amy Gallagher +6 more
wiley +1 more source
Missense Variants in the A Isoform of FGF13 as a Novel Cause of Paroxysmal Dyskinesia
Abstract Background Pathogenic variants within the unique N‐terminal inactivation particle of FGF13 isoform A (FGF13A) have so far been associated only with an X‐linked dominant epileptic encephalopathy (DEE). Objective The aim was to expand the clinical and molecular spectrum of FGF13A‐related disorder.
Cyril Mignot +22 more
wiley +1 more source
Abstract Objective To evaluate the effects of bilateral caudal zona incerta (cZi) deep brain stimulation (DBS) for Parkinson's disease (PD) one year after surgery and to create anatomical improvement maps based on patient‐specific simulation of the electric field.
Rasmus Stenmark Persson +6 more
wiley +1 more source
Therapeutic Spectrum of Intermittent Apomorphine in Parkinson's Disease: Neuropsychiatric, Behavioral, and Cognitive Analyses. [PDF]
Ünal ED.
europepmc +1 more source

